CC
CYTK icon

Carlson Capital’s Cytokinetics CYTK Stock Holding History

Carlson Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$635K – 77
2025
Q4 		$635K Buy
+10,000
New +$622K 0.23% 54

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Carlson Capital's CYTK Position: Q1 2026 in Review

Carlson Capital increased its Cytokinetics (CYTK) stake by 61% in Q1 2026, buying an estimated $216K and bringing the position to 9,000 shares worth $593K. The position accounts for 0.19% of the portfolio, ranked #60.

Carlson Capital first reported a position in CYTK in Q1 2024 and has held it in 7 quarters since. The position peaked at $2.07M in Q2 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Carlson Capital held 9,000 shares of Cytokinetics worth $593K as of Q1 2026.
  • Carlson Capital bought 3,400 Cytokinetics shares in Q1 2026, an estimated $216K.
  • Cytokinetics made up 0.19% of Carlson Capital's portfolio in Q1 2026, its #60 holding.
  • Carlson Capital first reported a position in Cytokinetics in Q1 2024 and has held it in 7 quarters since.
  • Carlson Capital's Cytokinetics position peaked at $2.07M in Q2 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Carlson Capital's 13F filing for Q1 2026, filed 28 May 2026.